Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Claret

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|January 15, 2014
Evaluation of tumor size response metrics to predict survival in oncology clinical trialsR Bruno, F Mercier, L Claret
Cancer Chemotherapy and Pharmacology|April 9, 2011
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancerN Frances, L Claret, R Bruno, et al.
Pharmaceutical Research|August 11, 2001
Fractal volume of drug distribution: it scales proportionally to body massV Karalis, L Claret, A Iliadis, et al.
Molecular Microbiology|March 17, 2001
The Escherichia coli histone-like protein HU regulates rpoS translationA Balandina, L Claret, R Hengge-Aronis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 10, 2002
Information tools for exploratory data analysis in population pharmacokineticsO Petricoul, L Claret, D Barbolosi, et al.
Clinical Pharmacology and Therapeutics|January 21, 2014
Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study resultsL Claret, R Bruno, J-F Lu, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast CancerR Bruno, L Lindbom, F Schaedeli Stark, et al.
Clinical Pharmacology and Therapeutics|August 23, 2012
Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancerL Claret, J-F Lu, R Bruno, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 13, 2016
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-AKelong Han, L Claret, Y Piao, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib UseF Jonsson, Y Ou, L Claret, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|January 15, 2014
Evaluation of tumor size response metrics to predict survival in oncology clinical trialsR Bruno, F Mercier, L Claret
Cancer Chemotherapy and Pharmacology|April 9, 2011
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancerN Frances, L Claret, R Bruno, et al.
Pharmaceutical Research|August 11, 2001
Fractal volume of drug distribution: it scales proportionally to body massV Karalis, L Claret, A Iliadis, et al.
Molecular Microbiology|March 17, 2001
The Escherichia coli histone-like protein HU regulates rpoS translationA Balandina, L Claret, R Hengge-Aronis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 10, 2002
Information tools for exploratory data analysis in population pharmacokineticsO Petricoul, L Claret, D Barbolosi, et al.
Clinical Pharmacology and Therapeutics|January 21, 2014
Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study resultsL Claret, R Bruno, J-F Lu, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast CancerR Bruno, L Lindbom, F Schaedeli Stark, et al.
Clinical Pharmacology and Therapeutics|August 23, 2012
Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancerL Claret, J-F Lu, R Bruno, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 13, 2016
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-AKelong Han, L Claret, Y Piao, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib UseF Jonsson, Y Ou, L Claret, et al.
Pageof 3